CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market CN Bio, a leading Organ-on-a-Chip (OOC)
CN Bio and Altis Biosystems partnership
CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies CN Bio and
PhysioMimix data supports Inipharm’s INI-822 for metabolic liver disease treatment
CN Bio PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing. CN Bio, a
OBN Awards 2023 winner!
CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA Six-year collaboration
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems CN Bio, a
CN Bio showcased in PwC UK’s ‘Life Sciences Future 50’ report 2023
We are delighted to announce that we are showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report. The report illustrates
Taking organoids to the next level
Organoids are miniaturized, simplified versions of human organs that self-organize in in vitro culture within a 3D cellular matrix. They are generally
A guide to pre-validating primary cells for use in Organ-on-a-chip assays
Mirror, mirror on the wall, which is the best cell of them all? If you are considering incorporating Organ-on-a-chip (OOC) technology into your
CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems
Partnership to provide customers with direct access to portfolio of highly characterized hepatic cells to recreate advanced Liver-on-a-Chip